Related Experiment Videos
Calcium antagonists after acute myocardial infarction
1Divisione di Cardiologia, Policlinico S. Matteo, IRCCS, Pavia, Italy.
Insights
Calcium-channel blockers show varied efficacy in myocardial infarction patients. Diltiazem improved survival in specific non-Q-wave myocardial infarction cases, unlike nifedipine or verapamil.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Efficacy and safety of calcium-channel blockers (CCBs) in myocardial infarction (MI) require further evaluation.
- Key issues include managing post-MI angina, preventing mortality and reinfarction, and addressing CCB cardiodepressant effects.
Purpose of the Study:
- To evaluate the efficacy and safety of CCBs in patients following myocardial infarction.
- To determine which CCB agents are most beneficial for specific patient subgroups.
Main Methods:
- Review of studies on CCB use in myocardial infarction patients.
- Analysis of CCB effects on myocardial oxygen supply and demand.
- Assessment of CCB cardiodepressant actions in vivo and in vitro.
Main Results:
- CCBs can increase oxygen supply or reduce demand, with drug choice depending on patient factors.
- Cardiodepressant effects are significant for verapamil, less so for diltiazem, and minimal for dihydropyridines.
- Nifedipine and verapamil showed no benefit in secondary MI prevention; diltiazem improved survival in non-Q-wave MI without left ventricular dysfunction.
Conclusions:
- CCBs have a complex role in post-MI care, with varying effects based on drug and patient profile.
- Diltiazem demonstrates a specific benefit in a subset of MI patients.
- Patient stratification is crucial to identify individuals who may benefit from CCB therapy.
Abstract:
Studies dealing with the evaluation of efficacy and safety of calcium-channel blocking agents in patients with myocardial infarction are not completely exhaustive. In this setting, three major issues have to be considered: the treatment of postinfarction angina, the prevention of sudden death and fatal or nonfatal reinfarction, and the potentially harmful inotropic action of these drugs. Calcium-channel blocking agents may exert their anti-ischemic effect either by increasing myocardial oxygen supply or by reducing myocardial oxygen demand, or both. The drug of choice will depend on the physiopathological setting of the individual patient and on the responsiveness to each specific compound (verapamil, dilitiazem, or dihydropyridines). The potential dangerous cardiodepressant action of this class of drugs, well documented in vitro, is sizable in vivo only for some of them (verapamil and derivatives, much less for diltiazem), but not for dihydropyridines. Thus, it does not generally represent a definite contraindication for patients also with potentially impaired left ventricular function. Up to the present, a number of studies have failed to demonstrate any beneficial effect of nifedipine and verapamil in the secondary prevention of myocardial infarction. Only diltiazem proved to be effective in increasing survival in patients with non-Q-wave myocardial infarction without left ventricular dysfunction. These data suggest the need for a careful stratification of patients into subgroups, in order to clarify who could actually benefit by these drugs.